Literature DB >> 20827517

Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?

Sulaf J Mansur1, Fadi G Hage, Suzanne Oparil.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays an important role in blood pressure control and volume homeostasis. Inappropriate activation of the RAAS has been implicated in the pathogenesis of hypertension and related cardiovascular disease. Several classes of agents that block RAAS signaling have been shown to be effective antihypertensives and to have cardioprotective and renoprotective properties. Because blockade of the RAAS is incomplete with any of the currently available monotherapies, combinations of these agents have been tested and shown to provide additional clinical benefit in patients with hypertension and various forms of cardiovascular and renal disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20827517     DOI： 10.1007/s11886-010-0140-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  58 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

Review 3.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

Review 4.  2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations.

Authors:  Norman R C Campbell; Janusz Kaczorowski; Richard Z Lewanczuk; Ross Feldman; Luc Poirier; Margaret Moy Kwong; Marcel Lebel; Finlay A McAlister; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2010-05       Impact factor: 5.223

5.  Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.

Authors:  V Mooser; J Nussberger; L Juillerat; M Burnier; B Waeber; J Bidiville; N Pauly; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1990-02       Impact factor: 3.105

6.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

7.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  Nephrol Dial Transplant       Date:  2009-01-14       Impact factor: 5.992

8.  Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.

Authors:  Yagiz Uresin; Addison A Taylor; Charles Kilo; Diethelm Tschöpe; Massimo Santonastaso; Ghionul Ibram; Hui Fang; Andrew Satlin
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2007-12       Impact factor: 1.636

9.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245
View more
  4 in total

1.  Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis.

Authors:  Maria Luigia Carbone; Gilliane Chadeuf; Sandrine Heurtebise-Chrétien; Xavier Prieur; Thibault Quillard; Yann Goueffic; Nathalie Vaillant; Marc Rio; Laure Castan; Maxim Durand; Céline Baron-Menguy; Julien Aureille; Juliette Desfrançois; Angela Tesse; Raul M Torres; Gervaise Loirand
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

2.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

Review 3.  Epigenetic Programming of Synthesis, Release, and/or Receptor Expression of Common Mediators Participating in the Risk/Resilience for Comorbid Stress-Related Disorders and Coronary Artery Disease.

Authors:  Carlos Manuel Zapata-Martín Del Campo; Martín Martínez-Rosas; Verónica Guarner-Lans
Journal:  Int J Mol Sci       Date:  2018-04-18       Impact factor: 5.923

Review 4.  The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling.

Authors:  Maricica Pacurari; Ramzi Kafoury; Paul B Tchounwou; Kenneth Ndebele
Journal:  Int J Inflam       Date:  2014-04-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.